brobert
/
LogseqFMS
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity

Auto saved by Logseq

Browse Source
master
Borja Robert 11 months ago
parent 91f7c3da08
commit 0ec9685a2b
1 changed files with 20 additions and 20 deletions
Show Stats Download Patch File Download Diff File

40
pages/STOP2030___Web.md
Unescape Escape View File

@ -13,30 +13,30 @@
- Develop a model for sustainable supply and costing
- Model the impact of different use cases and scenarios
- Pilot antihelmintic resistance surveillance based on genetic epidemiology
- ## Timeline y milestones (cuáles se han cumplido?)
- __Proposed safety and effectiveness study__
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
- *Secondary objectives*:
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[STH]] (T. trichiura, A. lumbricoides, hookworms) [[by]] microscopy
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[Strongyloides stercolaris]] [[by]] serology
- *Primary goal*: Safety (incidence of SAEs)
- *Secondary goals*: Effectiveness at 21 days and 1 [[year]]; Genomic resistance
- *Sample size*: approx. 20k.
- *Target population*: School based
- *Epidemiologic conditions of the sites*: T. trichiura ongoing transmission areas
- *Countries*: [[Ghana]] and [[Kenya]]
- __Proposed acceptability and feasibility study__
- *Primary goal*: Acceptability and feasibility
- *Secondary goals*: Adherence (3-day regimen), fidelity
- *Countries*: [[Ghana]] and [[Kenya]]
- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
-
- ## Objetivos y logros de los proyectos STOP previos (en background)
- Qualification at EMA for art. 58
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
- Timeline y milestones (cuáles se han cumplido?)
- __Proposed safety and effectiveness study__
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
- *Secondary objectives*:
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[STH]] (T. trichiura, A. lumbricoides, hookworms) [[by]] microscopy
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[Strongyloides stercolaris]] [[by]] serology
- *Primary goal*: Safety (incidence of SAEs)
- *Secondary goals*: Effectiveness at 21 days and 1 [[year]]; Genomic resistance
- *Sample size*: approx. 20k.
- *Target population*: School based
- *Epidemiologic conditions of the sites*: T. trichiura ongoing transmission areas
- *Countries*: [[Ghana]] and [[Kenya]]
- __Proposed acceptability and feasibility study__
- *Primary goal*: Acceptability and feasibility
- *Secondary goals*: Adherence (3-day regimen), fidelity
- *Countries*: [[Ghana]] and [[Kenya]]
- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
-
- ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
- Main results of previous STOP projects: ALIVE pivotal Trial
- ## Otros facts
- FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
- Investigadores principales de cada uno de los partners
- Ideas generales importantes
- Dosing strategies for Ivermectine are being revisited

Write Preview
Loading…
Cancel
Save